Cardiovascular diseases (CVDs). Cardiovascular disease, unspecified
Conditions
Interventions
Intervention 1: First intervention group: patients receiving 2 grams of sumac daily in 2 doses (1 gram capsules containing sumac). Intervention 2: Second intervention group: patients receiving daily 1
Sponsors
Yasouj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Completing and signing the informed consent form. Age between 20-75 years Patients hospitalized in the cardiac intensive care unit who have MI (myocardial infarction) based on a definitive diagnosis. Type 2 diabetes mellitus diagnosed by a doctor Body mass index (BMI)>25 Familiarity with Persian language and the ability to read and write
Exclusion criteria
Exclusion criteria: Pregnant and lactating people or people with mental illnesses, as well as patients with stomach ulcers or digestive disorders or other disorders affecting food metabolism. hypothyroidism or hyperthyroidism and any systemic disease (including liver, kidney, gout, rheumatoid arthritis and acute or chronic kidney failure) Allergy to sumac or cinnamon Users of psychotropic drugs, including antidepressants, anti-psychotics, anti-anxiety drugs Heart failure in stage IV Acute infections at the time of study entry Obstructive pulmonary diseases Treatment with sex hormones Use of medication interfering with the study Participation in another clinical study in the last 3 months People with any problems in understanding and filling the consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Low-density lipoprotein. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.;High-density lipoprotein. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods - Elisa Kit.;Very-low density lipoprotein. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.;Triglyceride. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods - Elisa Kit.;Total Cholesterol. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods - Elisa Kit.;Life Quality. Timepoint: At the beginning and end of the intervention period. Method of measurement: World Health Organization quality of life questionnaire bref.;Pain. Timepoint: At the beginning and end of the intervention period. Method of measurement: Mcgill pain questionnarie. | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin-6. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.;High sensitive C reactive protein (hs-CRP). Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods.;Complete blood count. Timepoint: At the beginning and end of the intervention period. Method of measurement: Laboratory methods. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAshkan Golmohammadi
Yasouj University of Medical Sciences
Outcome results
None listed